Teva's experimental antibody cuts intestinal damage in celiac patients after gluten challenge

Teva reported that a single injection of an experimental antibody markedly lowered intestinal damage in participants with celiac disease who continued to consume gluten daily.

The study was a gluten challenge trial, and the topline results showed a statistically significant reduction in villous atrophy compared with baseline.

Teva said the findings highlight the potential of targeting the IL-15 pathway for celiac disease, though further trials will be needed before regulatory submission.